Oxygen-independent free radical generation mediated by core-shell magnetic nanocomposites synergizes with immune checkpoint blockade for effective primary and metastatic tumor treatment

Nano Today ◽  
2021 ◽  
Vol 36 ◽  
pp. 101024
Author(s):  
Jin-Cheng Guo ◽  
Qiao An ◽  
Mengyu Guo ◽  
Yating Xiao ◽  
Bo Li ◽  
...  
Nano Letters ◽  
2021 ◽  
Author(s):  
Guoming Huang ◽  
Yuan Qiu ◽  
Feifei Yang ◽  
Jiangao Xie ◽  
Xin Chen ◽  
...  

2020 ◽  
Vol 12 (36) ◽  
pp. 40042-40051
Author(s):  
Wu-Yi Xiao ◽  
Yi Wang ◽  
Hong-Wei An ◽  
Dayong Hou ◽  
Muhetaerjiang Mamuti ◽  
...  

2018 ◽  
Vol 80 (1) ◽  
pp. 51-55
Author(s):  
Ai KAJITA ◽  
Osamu YAMASAKI ◽  
Tatsuya KAJI ◽  
Hiroshi UMEMURA ◽  
Keiji IWATSUKI

2019 ◽  
Vol 21 (1) ◽  
pp. 21-25 ◽  

Emerging results support the concept that Alzheimer disease (AD) and age-related dementia are affected by the ability of the immune system to contain the brain's pathology. Accordingly, well-controlled boosting, rather than suppression of systemic immunity, has been suggested as a new approach to modify disease pathology without directly targeting any of the brain's disease hallmarks. Here, we provide a short review of the mechanisms orchestrating the cross-talk between the brain and the immune system. We then discuss how immune checkpoint blockade directed against the PD-1/PD-L1 pathways could be developed as an immunotherapeutic approach to combat this disease using a regimen that will address the needs to combat AD.


2019 ◽  
Vol 21 (1) ◽  
pp. 21-25 ◽  

Emerging results support the concept that Alzheimer disease (AD) and age-related dementia are affected by the ability of the immune system to contain the brain’s pathology. Accordingly, well-controlled boosting, rather than suppression of systemic immunity, has been suggested as a new approach to modify disease pathology without directly targeting any of the brain’s disease hallmarks. Here, we provide a short review of the mechanisms orchestrating the cross-talk between the brain and the immune system. We then discuss how immune checkpoint blockade directed against the PD-1/PD-L1 pathways could be developed as an immunotherapeutic approach to combat this disease using a regimen that will address the needs to combat AD.


Sign in / Sign up

Export Citation Format

Share Document